A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).
Public ClinicalTrials.gov record NCT03137069. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot and Dose-Ranging Study of GDC-0853 in Patients With Refractory Chronic Spontaneous Urticaria (CSU).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of GDC-0853 compared with placebo in participants with Refractory Chronic Spontaneous Urticaria (CSU) already treated with anti-histamines. Participants have the option to enter the Open-Label Extension (OLE) study after completing the 8-week treatment period.
Study identification
- NCT ID
- NCT03137069
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 134 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 26, 2017 (Actual)
- Primary completion
- Sep 27, 2019 (Actual)
- Completion
- Oct 25, 2019 (Actual)
- Last update posted
- Sep 29, 2020
2017 – 2019
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Research Center of Alabama, LLC | Birmingham | Alabama | 35209 | — |
| Allergy & Asthma Immunology Associates | Scottsdale | Arizona | 85251 | — |
| Kern Allergy Med Clinic, Inc. | Bakersfield | California | 93301 | — |
| Southern California Research Center | Mission Viejo | California | 92691 | — |
| Allergy & Asthma Consultants | Redwood City | California | 94063 | — |
| Integrated Research Group Inc | Riverside | California | 92506 | — |
| Integrated Research of Inland | Upland | California | 91786 | — |
| New Horizon Research Center | Miami | Florida | 33165 | — |
| Renstar Medical Research | Ocala | Florida | 34470 | — |
| Vital Prospects Clinical Research Institute PC - CRN | Tulsa | Oklahoma | 74136 | — |
| Asthma, Nasal Disease, and Allergy Research Center of New England | East Providence | Rhode Island | 02914 | — |
| Center for Clinical Studies | Cypress | Texas | 77433 | — |
| Timber Lane Allergy and Asthma Research, LLC | Burlington | Vermont | 05403 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03137069, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2020 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03137069 live on ClinicalTrials.gov.